A new Danish study indicates that semaglutide, the active ingredient in weight loss and diabetes drugs Wegovy and Ozempic, could help individuals with alcohol problems by reducing consumption, heavy drinking days, and cravings.
Study Details
The 26-week trial involved 108 obese patients diagnosed with alcohol use disorder. Half of the participants received 2.4mg of semaglutide, while the other half received a placebo, in addition to talking therapy.
Key Findings
Participants treated with semaglutide saw a significant decrease in heavy drinking days, dropping from an average of 17 to approximately five per month. In contrast, the placebo group reduced to nine days. Overall alcohol consumption also reduced more substantially in the semaglutide group, decreasing from about 2,200g to 650g over a 30-day period, compared to 1,175g for the placebo group.
Experts suggest semaglutide may influence the biological mechanisms of addiction, offering a potential new treatment avenue. However, they emphasize the need for larger, longer-term trials across diverse populations before widespread clinical use.
The findings, published in a medical journal, add to growing evidence that GLP-1 receptor agonists like semaglutide could have broader therapeutic applications beyond diabetes and obesity. Researchers noted that the reduction in alcohol cravings was particularly promising, as cravings are a major driver of relapse in alcohol use disorder.
Dr. Anna Nielsen, lead author of the study from the University of Copenhagen, stated: "The importance of these results cannot be overstated. If replicated in larger studies, semaglutide could become a game-changer for the treatment of alcohol addiction."
However, she cautioned that the study was relatively small and limited to obese patients, so further research is needed to confirm the effects in normal-weight individuals and over longer periods.
